An Upgrade on the Rabbit Model of Anthracycline-Induced Cardiomyopathy: Shorter Protocol, Reduced Mortality, and Higher Incidence of Overt Dilated Cardiomyopathy
Table 1
Selected biochemical parameters.
Parameter
Basal
Intermediate
Final
Cholesterol (mg/dL)
Control
41.5 ± 10.3
37.5 ± 10.2
44.7 ± 3.8
DOX2
36.10 ± 11.25
70.46 ± 16.66
241.04 ± 59.5
DAU3
40.80 ± 4.34
45.66 ± 6.40
79.73 ± 8.20
DAU4
35.24 ± 7.71
44.38 ± 4.05
59.08 ± 7.81
Triglycerides (mg/dL)
Control
72.3 ± 22.9
45.3 ± 7.3
55.3 ± 7.1
DOX2
68.23 ± 17.48
184.70 ± 47.74
405.88 ± 38.80
DAU3
78.09 ± 20.39
150.31 ± 65.32
446.22 ± 102.9
DAU4
72.50 ± 22.85
85.04 ± 12.35
115.88 ± 15.72
Creatinine (mg/dL)
Control
0.86 ± 0.10
0.77 ± 0.11
0.83 ± 0.10
DOX2
0.93 ± 0.06
1.08 ± 0.08
1.62 ± 0.22
DAU3
0.79 ± 0.04
1.06 ± 0.10
2.54 ± 0.50
DAU4
0.98 ± 0.10
0.92 ± 0.10
0.87 ± 0.07
BUN (mg/dL)
Control
37.00 ± 4.95
38.54 ± 6.62
41.79 ± 8.50
DOX2
36.43 ± 3.45
30.50 ± 3.74
39.40 ± 8.69
DAU3
26.61 ± 2.99
30.92 ± 2.47
85.47 ± 12.34
DAU4
35.42 ± 4.57
28.35 ± 1.38
29.96 ± 2.50
Total Proteins (g/dL)
Control
5.39 ± 0.21
5.37 ± 0.22
5.33 ± 0.24
DOX2
5.48 ± 0.17
4.90 ± 0.37
3.92 ± 0.37
DAU3
5.31 ± 0.17
5.90 ± 0.30
4.42 ± 0.81
DAU4
5.55 ± 0.16
5.20 ± 0.12
4.96 ± 0.17
AST (U/L)
Control
23.02 ± 4.90
18.47 ± 4.10
20.77 ± 4.34
DOX2
27.59 ± 4.71
24.36 ± 6.86
30.42 ± 1.01
DAU3
20.96 ± 2.93
22.72 ± 5.82
270.9 ± 124.0
DAU4
35.94 ± 5.73
23.30 ± 3.84
28.31 ± 5.67
ALT (U/L)
Control
44.67 ± 8.16
39.97 ± 7.89
37.45 ± 7.37
DOX2
53.02 ± 5.34
36.98 ± 7.45
35.46 ± 4.30
DAU3
48.75 ± 6.47
54.56 ± 12.34
226.70 ± 97.2
DAU4
58.25 ± 13.44
45.03 ± 5.96
42.19 ± 6.88
Intermediate time point values were from blood samples obtained on week 8 of the study in control group, on week 6 in DOX2 group, on week 8 in DAU3 group, and on week 4 in DAU4 group. BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Data expressed as mean ± SEM. Statistical significance is at p < 0.05; compared to basal value; compared to control; compared to DOX2; #compared to DAU3; compared to DAU4.
